Skip to main content

The Brainclinics Foundation

Applied Neuroscience from the clinic,to the clinic

Research Institute Brainclinics was founded in 2001 as an independent research institute and specializes in advancing our understanding of the brain; applied neuroscience to improve treatments for ADHD, Depression and OCD.  The results of our research are a valuable aid in the treatment and prevention of symptoms such as mood-, concentration-, impulse control-, and sleep-problems, often seen in disorders such as depression, ADHD, and insomnia. Our expertise extends to the development and application of brain stimulation techniques, such as rTMS for depression and OCD, TMS induced Heart-Brain Coupling and EEG based precision psychiatry and stratified psychiatry for Depression and ADHD.

Masterclass

Our TMS Masterclass & Certification course takes you from the basics of TMS and Brain Stimulation, to exciting new developments in this field with world renown speakers from all over the...

Resources

Get access to our Brainclinics resources, such as books, theses and the open access TDBRAIN EEG dataset with more than 1200 EEG’s and descriptive data.

Research

Read more about our scientific publications and articles over the years.

Citations

9996

Publications

255

Co-authors

765

News

We regularly post news on Linkedin. Please follow us on Linkedin to get the latest news in your Linkedin feed. 

27 March 2025
Last Monday Lauren Zwienenberg succesfully defended here PhD titled: The Heart-Brain Dialogue: Pathways to TMS Treatment Optimization, at Maastricht University. Congrats Dr. Zwienenberg! Thanks Alexander Sack, Hanneke van Dijk & Martijn Arns as supervisory team and Bernadette M. Jansma, Bart Rutten, Diego Candia-Rivera, Odile A. van den Heuvel, Pim Drinkenburg, Marie-José van Tol 🟥 🎗️ & Teresa Schuhmann for your contribution to the reading commi...
23 March 2025
Wrapping-up 25 years of EEG-history: We just donated 8 EEG systems to TeleEEG® (Steve Coates & Anne Clarke) to support epilepsy diagnostics in developing countries. If you have working EEG amplifiers, consider donating to TeleEEG® : https://www.teleeeg.org/ Donation also made possible by Synaeda, Bob Goeree, Rien Breteler, PhD, BCN, Ad Denissen.
16 March 2025
🎯 Master TMS with Leading Experts: Brainclinics TMS Masterclass and Certification Course 2025
09 March 2025
Thrilled to announce our publication in Brain Stimulation Journal on the largest case series to date on right OFC-TMS as an add-on to standard left DLPFC-TMS in major depression. A big thank-you to Salience Health for contributing data on over 3500 patients, and to our phenomal co-authors including Martijn Arns, Victoria Middleton, Jennifer Bowman, Nancy Donachie, Joseph Kriske, John Kriske, Alexander Sack, Nikita van der Vinne, Jonathan Downa...
28 February 2025
Aandacht in FD voor ons initiatief om behandeling van ernstige depressie met behulp van ketamine in Nederland toegankelijk te maken op zorgvuldige en kosteneffectieve wijze: www.phida.nl https://lnkd.in/eKPxuPUm Marc Scot Aline de Haan Jet Kranendonk Het Financieele Dagblad Alwine de Jong Maarten van Poll #depressie #depressiebehandeling #ketamine #psychiatrie #ggz
30 January 2025
Large piece in Dutch newspaper on use of Brainmarker-I (alpha frequency based EEG biomarker) in clinical practice. Congrats Nikita van der Vinne and Synaeda. See links in comments below re further scientific backgrounds and validation studies. https://lnkd.in/eefsXeqc
30 January 2025
Bij een Friese ggz-instelling krijgen patiënten met een depressie medicatie voorgeschreven op basis van hersenonderzoek. ‘Onze werkwijze is geen wondermiddel’, zegt gezondheidszorgpsycholoog Nikita van der Vinne. ‘Wij kunnen niet met zekerheid voorspellen welk middel voor jou werkt. Wat we wel kunnen zien is bij welk middel de kans groter is dat het aanslaat.’ Lees meer via deze link: https://lnkd.in/dJgFY5iE
30 January 2025
Congrats Synaeda and Nikita van der Vinne, great to see a good piece on Brainmarker-I use in Depression in one of the major newspapers! And that's only on stratification between antidepressants, not even including stratification between TMS protocols!
30 December 2024
TMS is cost-effective for treatment resistant depression relative to the next pharmacological treatment step. Congrats Iris Dalhuisen and colleagues. https://lnkd.in/eeShN5Uj
30 November 2024
Look forward to, see you there?

Follow us: